SRRK – Scholar Rock Holding Corp
Scholar Rock Holding CorporatioSRRK
$44.21Name : Scholar Rock Holding Corporatio
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $5,393,818,112.00
EPSttm : -3.23
Scholar Rock Holding Corporatio
$44.21
5.13%$2.39
SRRK — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
23.3
Margin Of Safety %
Put/Call OI Ratio
0.68
EPS Next Q Diff
EPS Last/This Y
0.08
EPS This/Next Y
0.58
Price
46.53
Target Price
69.12
Analyst Recom
1.11
Performance Q
-12.17
Upside
-352.4%
Beta
0.78
Ticker: SRRK
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-13 | SRRK | 40.53 | 0.75 | 1.04 | 14195 |
| 2026-10-14 | SRRK | 39.6 | 0.70 | 2.44 | 13826 |
| 2026-10-15 | SRRK | 40.61 | 0.70 | 0.05 | 13804 |
| 2026-10-16 | SRRK | 39.91 | 0.68 | 1.30 | 13996 |
| 2026-10-19 | SRRK | 40.29 | 0.96 | 0.06 | 9893 |
| 2026-10-20 | SRRK | 41.39 | 0.93 | 0.55 | 10094 |
| 2026-10-21 | SRRK | 43.05 | 0.89 | 0.20 | 11044 |
| 2026-10-22 | SRRK | 41.97 | 0.86 | 0.08 | 11390 |
| 2026-10-23 | SRRK | 41.48 | 0.85 | 9.34 | 11524 |
| 2026-10-26 | SRRK | 41.74 | 0.70 | 0.48 | 10858 |
| 2026-10-27 | SRRK | 42.51 | 0.70 | 0.49 | 10897 |
| 2026-10-28 | SRRK | 43.26 | 0.71 | 0.35 | 10916 |
| 2026-10-29 | SRRK | 44.38 | 0.70 | 0.38 | 11069 |
| 2026-10-30 | SRRK | 43.89 | 0.69 | 0.06 | 11156 |
| 2026-11-02 | SRRK | 43.07 | 0.69 | 0.12 | 11244 |
| 2026-11-03 | SRRK | 43.99 | 0.69 | 0.04 | 11245 |
| 2026-11-04 | SRRK | 46.08 | 0.69 | 0.29 | 11299 |
| 2026-11-05 | SRRK | 45.49 | 0.69 | 0.00 | 11353 |
| 2026-11-06 | SRRK | 46.92 | 0.69 | 3.19 | 11370 |
| 2026-11-09 | SRRK | 51.58 | 0.69 | 0.97 | 11434 |
| 2026-11-10 | SRRK | 47.95 | 0.75 | 0.05 | 13540 |
| 2026-11-11 | SRRK | 46.55 | 0.68 | 0.07 | 14353 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-13 | SRRK | 40.56 | 7.2 | - | -3.21 |
| 2026-10-14 | SRRK | 39.56 | 6.8 | - | -3.22 |
| 2026-10-15 | SRRK | 40.60 | 6.8 | - | -3.22 |
| 2026-10-16 | SRRK | 39.92 | 6.8 | - | -3.22 |
| 2026-10-19 | SRRK | 40.26 | 6.8 | - | -3.22 |
| 2026-10-20 | SRRK | 40.26 | 6.8 | - | -3.22 |
| 2026-10-21 | SRRK | 41.39 | 6.8 | - | -3.22 |
| 2026-10-22 | SRRK | 41.99 | 6.8 | - | -3.22 |
| 2026-10-23 | SRRK | 41.46 | 6.8 | - | -3.22 |
| 2026-10-26 | SRRK | 41.72 | 6.2 | - | -3.21 |
| 2026-10-27 | SRRK | 42.54 | 6.2 | - | -3.21 |
| 2026-10-28 | SRRK | 43.26 | 6.2 | - | -3.21 |
| 2026-10-29 | SRRK | 44.14 | 6.2 | - | -3.21 |
| 2026-10-30 | SRRK | 43.89 | 6.2 | - | -3.21 |
| 2026-11-02 | SRRK | 42.92 | 6.2 | - | -3.21 |
| 2026-11-03 | SRRK | 43.99 | 6.2 | - | -3.21 |
| 2026-11-04 | SRRK | 46.10 | 6.2 | - | -3.21 |
| 2026-11-05 | SRRK | 45.48 | 6.2 | - | -3.21 |
| 2026-11-06 | SRRK | 46.89 | 6.2 | - | -3.21 |
| 2026-11-09 | SRRK | 51.60 | 6.2 | - | -3.21 |
| 2026-11-10 | SRRK | 47.98 | 6.2 | - | -3.21 |
| 2026-11-11 | SRRK | 46.53 | 6.2 | - | -3.21 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-13 | SRRK | -0.38 | 4.60 | 22.57 |
| 2026-10-14 | SRRK | -0.38 | 4.60 | 22.57 |
| 2026-10-15 | SRRK | -0.38 | 4.60 | 22.57 |
| 2026-10-16 | SRRK | -0.38 | 4.60 | 22.57 |
| 2026-10-19 | SRRK | -0.38 | 4.60 | 22.55 |
| 2026-10-20 | SRRK | -0.38 | 4.60 | 22.55 |
| 2026-10-21 | SRRK | -0.08 | 4.60 | 22.55 |
| 2026-10-22 | SRRK | -0.08 | 4.60 | 22.55 |
| 2026-10-23 | SRRK | -0.08 | 4.60 | 22.55 |
| 2026-10-26 | SRRK | -0.08 | 4.41 | 22.55 |
| 2026-10-27 | SRRK | -0.08 | 4.41 | 22.01 |
| 2026-10-28 | SRRK | 1.31 | 4.41 | 22.01 |
| 2026-10-29 | SRRK | 1.31 | 4.41 | 22.01 |
| 2026-10-30 | SRRK | 1.31 | 4.41 | 22.01 |
| 2026-11-02 | SRRK | 1.31 | 4.36 | 22.01 |
| 2026-11-03 | SRRK | 1.31 | 4.36 | 22.01 |
| 2026-11-05 | SRRK | 1.31 | 4.36 | 22.01 |
| 2026-11-06 | SRRK | 1.31 | 4.36 | 22.01 |
| 2026-11-09 | SRRK | 1.31 | 4.52 | 22.01 |
| 2026-11-10 | SRRK | 1.31 | 4.52 | 22.01 |
| 2026-11-11 | SRRK | 1.31 | 4.52 | 23.30 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
Avg. EPS Est. Current Quarter
-0.84
Avg. EPS Est. Next Quarter
-0.75
Insider Transactions
1.31
Institutional Transactions
4.52
Beta
0.78
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
5
Fair Value
Quality Score
17
Growth Score
25
Sentiment Score
82
Actual DrawDown %
24.7
Max Drawdown 5-Year %
-86.8
Target Price
69.12
P/E
Forward P/E
PEG
P/S
9956.47
P/B
33.69
P/Free Cash Flow
EPS
-3.36
Average EPS Est. Cur. Y
-3.21
EPS Next Y. (Est.)
-2.64
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-72563.16
Relative Volume
0.86
Return on Equity vs Sector %
-100
Return on Equity vs Industry %
-100
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.01
EBIT Estimation
◆
SRRK
Healthcare
$46.60
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
53.6
Range 1M
58.2%
Sup Dist
1%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
5.1%
EPS NY
16.7%
52W%
53.2%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+48.3% upside
Upside
+48.3%
Quality
17
SRRK — P/E HistoricalBiotechnology
Scholar Rock Holding CorporatioSector: Healthcare
Industry: Biotechnology
Employees: 289
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. The company is developing Apitegromab, an inhibitor of the activation of myostatin, which is in a Phase 2 clinical trial for the treatment of SMA and facioscapulohumeral muscular dystrophy (FSHD). Additionally, SRK-439, an anti-pro/latent myostatin antibody, is in a Phase 1 clinical trial for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. SRK-181 is a Phase 2-ready investigational inhibitor of latent TGFß1 for the treatment of patients with solid tumors that are resistant to anti-PD-(L)1 antibody therapies. The company also offers products in pre-clinical development, including SRK-373, a selective inhibitor of the latent TGFß1 isoform with selective activity in the fibrotic extracellular matrix, for the treatment of fibrotic diseases, and SRK-256, an inhibitor of RGMc, or hemojuvelin, for the treatment of iron-restricted anemias. Scholar Rock Holding Corporation is also developing a pipeline that includes programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
SRRK
Latest News
—
Caricamento notizie per SRRK…
stock quote shares SRRK – Scholar Rock Holding Corp Stock Price stock today
news today SRRK – Scholar Rock Holding Corp stock forecast ,stock prediction 2023 2024 2025
marketwatch SRRK – Scholar Rock Holding Corp yahoo finance google finance
stock history SRRK – Scholar Rock Holding Corp invest stock market
stock prices SRRK premarket after hours
ticker SRRK fair value insiders trading